Masitinib (4.5)

DRUG4 trials

Sponsors

AB Science

Conditions

Alzheimer DiseaseAmyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS)Progressive Multiple Sclerosis

Phase 2

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

CompletedNCT02588677

AB ScienceAmyotrophic Lateral Sclerosis (ALS)

Start: 2013-04-30End: 2018-03-31Updated: 2023-09-29

Phase 3

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

RecruitingNCT03127267

AB ScienceAmyotrophic Lateral Sclerosis

Start: 2021-02-02End: 2027-12-31Target: 495Updated: 2025-09-12

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

SuspendedNCT05441488

AB ScienceProgressive Multiple Sclerosis

Start: 2022-06-28End: 2028-12-01Target: 800Updated: 2026-05-06

Masitinib in Patients With Mild Alzheimer's Disease

Not yet recruitingNCT05564169

AB ScienceAlzheimer Disease

Start: 2026-06-30End: 2029-12-31Target: 600Updated: 2025-10-03

Related Papers

Masitinib Shows Prolonged Survival in Amyotrophic Lateral Sclerosis (ALS) Patients with Mild or Moderate Disease Severity at Baseline (S33.003)

Neurology2023-04-251 citations

Long-term survival analysis of masitinib in amyotrophic lateral sclerosis

Therapeutic Advances in Neurological Disorders2021-01-0163 citations